MedTrace Logo

Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa

NCT07006246 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1900

Last updated 2025-06-05

No results posted yet for this study

Summary

This is a funded implementation study designed to evaluate the efficacy of recruiting and retaining high-risk individuals on pre-exposure prophylaxis (PrEP) within multiple private pharmacies (and online platforms in South Africa)

Conditions

  • HIV Infection

Interventions

DRUG

Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)

Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Professor Francois Venter

    lead OTHER

Principal Investigators

  • Fanscois Venter, PhD in Medicine · Ezintsha, a subdivision of Wits Health Consortium

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-19
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07006246 on ClinicalTrials.gov